Chagas Disease - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the drug development landscape of the development of drug for Chagas disease including molecules at pre-clinical, discovery, and other development stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapies employed, preferred route of administration, therapeutic modality, targets for drugs under development, and mechanism of action.

Overview of the drug development pipeline for Chagas disease

Chagas disease is also known as American trypanosomiasis as it is caused by Tryopanosoma cruzi. It is a vector-borne disease and has two phases, i.e., acute phase and the chronic phase. A patient in chronic phase experiences cardiac and intestinal complications. Patients suffering from this condition experience symptoms such as diarrhea, enlarged lymph glands, and heart inflammation and meningoencephalitis.

Many organizations such as the World Health Organization and Drugs for Neglected Diseases initiatives (DNDi) are developing a low-cost drug for the treatment of Chagas disease by collaborating with various pharmaceutical companies. Technavio’s market research analysts have predicted that with the introduction of such medicines as one of the most promising approaches to treat Chagas disease, the Chagas disease treatment industry size will grow in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the discovery development stage. For instance, sponsors such as Astellas Pharma developed Novel compound and Savant HWP developed 18-MC, which are under discovery development stage. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under phase I, phase II, and phase III development stages. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are in the pre-clinical stage.

Chagas disease treatment market value: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of Chagas disease. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Bayer
• Eisai
• Kancera

Therapeutic assessment of the drug development pipeline for Chagas disease by preferred route of administration

• Oral
• Undisclosed

According to Chagas disease treatment market insights, the oral route of administration (ROA) involves the administration of drug substances through a mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration.

Therapeutic assessment of the drug development pipeline for Chagas disease by therapeutic modality

• Small molecule
• Vaccine

According to this pipeline analysis report, the majority of molecules that are currently in the drug development pipeline for a Chagas disease are being developed as small molecules. Small molecules are chemically manufactured active substances that are able to enter the cells easily because of their low molecular weight.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for Chagas disease?
• What are the companies that are currently involved in the development of drug development molecules for Chagas disease?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.